Nest And Care Strengthens Its Commitment to Exceptional Senior Home Care in Bethesda, MD
Bethesda, MD - Nest And Care, a trusted leader in senior home care, reaffirms its dedication to providing exceptional in-home care services in Bethesda, MD. Under the leadership of Kat Villanueva, the company continues to set the gold standard for compassionate, personalized care, offering seniors the support they need to age comfortably at home while giving families peace of mind.
As the need for high-quality senior care grows, Nest And Care remains committed to helping families navigate the challenges of aging with dignity and confidence. The company's team of highly trained caregivers delivers tailored care solutions designed to meet each client's unique needs, ensuring seniors can thrive in the safety and familiarity of their own homes.
'At Nest And Care, we recognize that choosing care for a loved one is one of life's most important decisions,' said Kat Villanueva, Founder and CEO. 'Our mission is to go beyond basic care—to provide companionship, support, and a sense of security that allows seniors and their families to feel truly at ease.'
The company offers a comprehensive range of services, including assistance with daily activities, medication management, meal preparation, transportation, and specialized care for conditions such as dementia and Alzheimer's. Through individualized care plans, Nest And Care ensures that every senior receives the personalized attention they need to maintain their independence and quality of life.
For families in Bethesda seeking a reliable and compassionate senior care provider, Nest And Care continues to be the trusted choice. With a reputation built on excellence, professionalism, and genuine care, the company remains a pillar of support for the community.
For more information about Nest And Care and its senior home care services in Bethesda, MD, visit https://nestandcare.com.
Media Contact
Company Name: Nest And Care
Contact Person: Kat Villanueva
Email: Send Email
Phone: +1 213 448 9798
Address: 10411 Motor City Dr Suite 325
City: Bethesda
State: Maryland 20817
Country: United States
Website: https://nestandcare.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
an hour ago
- National Post
Genentech and Roche Present New Insights in Alzheimer's Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC
Article content – Trontinemab's Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining <5% – Article content – Design of the Phase III TRONTIER 1 and 2 studies of trontinemab in early symptomatic Alzheimer's disease featured, with initiation planned in 2025 – Article content Article content – Plans for new Phase III trial investigating trontinemab in preclinical Alzheimer's disease, in people at high risk of cognitive decline – Article content – New real-world data support Elecsys pTau217 as a standalone blood test, comparable to a PET scan, for rule-in and rule-out identification of amyloid pathology – Article content SOUTH SAN FRANCISCO, Calif. — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer's development portfolio is being presented at the Alzheimer's Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer's across the entire patient journey. Article content Featured oral presentations include the latest results from the ongoing Phase Ib/IIa Brainshuttle™ AD study, which continue to support rapid and robust reduction of amyloid plaques, and design of the Phase III TRONTIER 1 and 2 studies of investigational trontinemab for early symptomatic Alzheimer's disease, with initiation planned later this year. As part of its growing Alzheimer's development program, Roche announced today its plans for an additional Phase III trial to investigate trontinemab in preclinical Alzheimer's disease. The trial will focus on individuals at risk of cognitive decline, with the goal of potentially delaying or preventing the progression of the disease to symptomatic stages. Article content 'Alzheimer's disease represents one of the greatest challenges in healthcare today and tackling it requires early detection and effective therapeutics,' said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. 'Trontinemab is designed to target a key driver of Alzheimer's disease biology more effectively in the brain. Combining new treatment avenues with advanced diagnostics may enable earlier and potentially more effective intervention. With plans for Phase III trials in both early symptomatic and preclinical Alzheimer's disease, we are advancing science with the goal of delaying—and ultimately preventing—progression of this devastating condition.' Article content Late-breaking oral and poster presentations highlight the potential of Roche's Elecsys ® pTau217 as a reliable and accessible blood-based biomarker test, providing comparable results to PET scan and cerebrospinal fluid (CSF) diagnostics for rule-in and rule-out diagnosis of amyloid pathology, a hallmark of Alzheimer's disease, across care settings. The test, which received Breakthrough Device Designation from the U.S. Food and Drug Administration last year, will also be utilized in Roche's TRONTIER studies. Article content 'Blood based testing for Alzheimer's disease has the potential to greatly improve patient access and decrease the time to definitive disease diagnosis,' said Matt Sause, CEO of Roche Diagnostics. 'Our data show that the Elecsys pTau217 test performs comparably to PET scans but can be performed with a simple blood draw and analyzed in a routine clinical laboratory. This has the potential to transform the diagnosis of Alzheimer's and provide clear answers to caregivers, patients, and their families.' Article content Up to 75% of people living with symptoms of Alzheimer's disease globally have not been diagnosed, and those who have, waited an average of 2.8 years, and even less have received any form of treatment. Diagnostics play a crucial role in addressing the global challenge of Alzheimer's, not only to detect and identify people with the disease early, even before the first symptoms, but also to rule out those who may or may not benefit from specific treatments. Article content Pharmaceuticals Article content In a 90-minute Featured Research session, designs were shared for the Phase III studies, TRONTIER 1 and 2, which will initiate later this year, investigating the efficacy and safety of investigational trontinemab in people with early Alzheimer's disease. The primary endpoint will measure the change in cognition and function based on the Clinical Dementia Rating – Sum of Boxes scale after 18 months of treatment. Secondary endpoints will include assessments of cognition, function, behavioral symptoms, and quality of life. A pre-screening study, TRAVELLER, based on a brief clinical assessment and a plasma biomarker, which will be identified using the Elecsys pTau217 test, has also been initiated, to enable broader community outreach and extend access to these trials to more diverse populations representative of Alzheimer's disease. Article content New data on the latest results for trontinemab from the completed dose-expansion part of the 1.8 mg/kg and 3.6 mg/kg cohorts from the ongoing Phase Ib/IIa Brainshuttle AD study continued to show rapid and robust reduction of amyloid plaques in the brain as measured by amyloid positron emission tomography (PET). In the 3.6 mg/kg cohort, trontinemab reduced amyloid levels below the 24 centiloid positivity threshold in 91% of participants (n=49/54) after 28 weeks of treatment; 72% (n=39/54) achieved deep clearance below 11 centiloids. Article content These data were reinforced by early and significant reductions in fluid biomarkers of Alzheimer's disease, including total tau, phosphorylated Tau (pTau)181, pTau217, and neurogranin measured in CSF and continues to show a favourable safety and tolerability profile. Amyloid-related imaging abnormalities-edema/effusion (ARIA-E) continued to be observed in <5% of participants (blinded data; N=4/149 across 1.8 and 3.6 mg/kg dose cohorts). All cases were radiographically mild, one was associated with mild and transient symptoms. Article content Diagnostics Article content Roche will present data on a new study comparing the pTau217/Ab42 plasma ratio to the high-throughput, fully automated Elecsys pTau217 assay. The presentation will report on the accuracy of these tools in detecting amyloid pathology. Together with the high throughput and full automation of the assay, these data will assess the potential of Elecsys pTau217 as an accurate standalone rule-in and rule-out test that could be scaled up for broad implementation in routine clinical practice worldwide. Article content Additionally, results from a cohort-based model of healthcare utilization in the U.S. demonstrated that using the Elecsys ® pTau181 blood-based rule-out test in primary care scenarios improved diagnostic accuracy and reduced resource use compared with the current standard-of-care clinical, cognitive and imaging tests. If made available in primary care settings, the Roche Elecsys ® pTau181 blood test has the potential to reliably avoid the need for further confirmatory testing in nearly all people who receive a negative result. This will avoid the need for these people to undergo unnecessary testing using CSF or PET, which often come with long wait times and high cost, resulting in further delays to diagnosis and cost to healthcare systems. Article content Medicine Abstract title Presentation number (type) Presentation date (session) Time Abstracts will be available on the AAIC website. Pharmaceuticals Next wave of innovation in Alzheimer's disease therapeutics: The value of novel active transport mechanisms Featured Research Session (FRS), Talk 1 Room 718 27 July 2025, 2pm – 3:30pm EDT Cath Mummery, Roberto Villaseñor, Jens Niewoehner, Scarlett Barker, Luka Kulic Latest results from the dose-expansion part (Part 2) of the Brainshuttle™ AD study of trontinemab in people with Alzheimer's disease Featured Research Session (FRS), Talk 2 Room 718 27 July 2025, 2pm – 3:30pm EDT Luka Kulic, Fabien Alcaraz, Gregory Klein, Stephen Salloway, Carsten Hofmann, João A. Abrantes, Stella Yilmaz, Denise Sickert, Maddalena Marchesi, Jakub Wojtowicz, Andres Schneider, Ruth Croney, David Agnew, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel Interim biomarker results for trontinemab, a novel Brainshuttle™ antibody in development for the treatment of Alzheimer's disease Featured Research Session (FRS), Talk 3 Room 718 27 July 2025, 2pm – 3:30pm EDT Gregory Klein, Gil Rabinovici, Henrik Zetterberg, Matteo Tonietto, Tobias Bittner, Daria Rukina, Fabien Alcaraz, Carsten Hofmann, Maddalena Marchesi, Jakub Wojtowicz, Ruth Croney, David Agnew, João A. Abrantes, Franziska Schaedeli Stark, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel, Luka Kulic TRONTIER 1 and TRONTIER 2: Pivotal trials of trontinemab in early symptomatic Alzheimer's disease Featured Research Session (FRS), Talk 4 Room 718 27 July 2025, 2pm – 3:30pm EDT Janice Smith, Catherine Mummery, Jeffrey L. Cummings, Gil Rabinovici, Stephen Salloway, Reisa Sperling, Henrik Zetterberg, Angeliki Thanasopolou, Christopher Lane, Paul Delmar, Gregory Klein, Ruth Croney, Jakub Wojtowicz, Carsten Hofmann, Luka Kulic, Hideki Garren Diagnostics Evaluating the Impact on Diagnostic Performance and Healthcare Resource Utilization of Introducing a plasma rule-out test in the Alzheimer's Disease Diagnostic Pathway Poster #102729 27 July 2025, 7:30am – 4:15pm EDT Sophie Roth, Gustaf Ortsäter, Joana Amorim Freire Location tbc Evaluating the Clinical Performance of the Elecsys pTau217 Plasma Immunoassay to Detect Amyloid Pathology in a Routine Clinical Practice Cohort Poster #96679 28 July 2025, 7:30am – 4:15pm EDT Sayuri Hortsch, Niels Borlinghaus, Alexander Jethwa, David Caley, Annunziata Di Domenico, Craig Ritchie Clinical performance and effect of pre-analytical variation of plasma pTau217 alone versus the plasma pTau217/Aβ42 ratio for the identification of amyloid pathology Oral Developing Topics #108585 3-23-DEV Developing Topics on Tau Biomarkers 29 July 2025, 2:00pm – 3:30pm EDT Christopher M. Rank, Joana Amorim Freire, Alexander Jethwa, Annunziata Di Domenico, Christina Rabe, Marc Suárez-Calvet, Colin L. Masters, Tobias Bittner Accuracy of cerebrospinal fluid biomarker ratios to determine amyloid positron-emission tomography status: a diagnostic test accuracy meta-analysis Poster #100941 28 July 2025, 7:30am – 4:15pm EDT Pablo Martinez-Lage, Eino Solje, Julian G. Martins, Sraboni Sarkar Equity in diagnosis through adequate clinical trial design in diagnostic performance studies Poster #102804 30 July 2025, 7:30am – 4:15pm EDT Imke Kirste, David Caley, Clara Quijano Rubio, Margherita Carboni Investigating Differences in Patients Enrolled in a Clinical Study Based on Referral Type Poster #108110 30 July 2025, 7:30am – 4:15pm EDT Sophie Roth, Laura Schlieker, Sayuri Hortsch, Joana Amorim Freire, David Caley Article content About trontinemab Article content Trontinemab is an investigational Brainshuttle bispecific 2+1 amyloid-beta targeting monoclonal antibody specifically engineered for enhanced access to the brain to enable rapid reduction of amyloid in people with Alzheimer's disease. Trontinemab is designed for the efficient transport across the blood-brain barrier to target aggregated forms of amyloid beta and remove amyloid plaques in the brain. Article content The uniqueness of trontinemab is based on Roche's proprietary Brainshuttle technology combining an amyloid beta-binding antibody with a transferring receptor (TfR1) shuttle module. As a result, high central nervous system (CNS) exposure of trontinemab may be achieved at low doses, leading to a rapid and deep amyloid clearance. Due to its unique properties, trontinemab might unlock the full potential of disease-modifying monoclonal antibodies by effectively penetrating the brain and potentially leading to slowing of disease progression. Article content About Roche in Alzheimer's Disease Article content With more than two decades of scientific research in Alzheimer's disease, Roche is working towards a day when we can detect and treat the disease early, in order to slow down, stop or even prevent its progression to preserve what makes people who they are. Today, the company's Alzheimer's disease portfolio spans investigational medicines for different targets, types and stages of the disease, including trontinemab. On the diagnostics side, it also includes approved and investigational tools, including digital and blood-based tests and CSF assays, aiming to more effectively detect, diagnose and monitor the disease. Yet the global challenges of Alzheimer's disease go well beyond the capabilities of science, and making a meaningful impact requires collaboration both within the Alzheimer's community and outside of healthcare. Roche will continue to work together with numerous partners with the hope to transform millions of lives. Article content About Genentech in Neuroscience Article content Neuroscience is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases. Article content Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer's disease, Huntington's disease, Parkinson's disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today. Article content Article content Article content Article content Article content
Globe and Mail
14 hours ago
- Globe and Mail
Codex Labs to Exhibit at The Society for Pediatric Dermatology's 50th Annual Meeting
Seattle, Wash. - July 22nd, 2025 - Codex Labs, a biotech skincare company focused on microbiome-friendly solutions, is honored to participate in The Society for Pediatric Dermatology's (SPD) 50th Annual Meeting. Taking place from July 23rd to 26th at The Westin Seattle, the event will celebrate five decades of advancing pediatric dermatology through education, research, and collaboration. "Codex Labs is delighted to be attending The Society for Pediatric Dermatology's 50th Annual Meeting and presenting a novel plant-based biotech eczema lotion and cleanser for children as young as 3 weeks old,' says founder and CEO Dr. Barbara Paldus. 'We believe that these new topicals, when combined and targeted with pre- and probiotics, will usher in a future of highly effective, steroid-free alternatives for the management of pediatric atopic dermatitis." The SPD comprises over 1,800 members worldwide, including pediatricians, dermatologists, pediatric dermatologists, and other healthcare professionals. At this year's milestone 50th SPD Annual Meeting, Codex Labs will be one of many organizations gathering to support the advancement of pediatric dermatology. The SPD's 50th Annual Meeting will take place over four days and feature networking opportunities, support group discussions, lecture sessions, companies and exhibitors showcasing their products, and organizations dedicated to pediatric dermatology research and advancement. Some key topics highlighted at this year's meeting include infections, medications and therapies, psoriasis and inflammatory skin conditions, tumors and neoplasms, vascular lesions, and more. Codex Labs will be attending this year's 50th Annual Meeting and sponsoring the Early Career Networking Reception on Wednesday, July 23rd at 6:00 pm. This event is for medical doctors completing a fellowship or those out of training for five years or less, where they can share experiences and connect with other young dermatologists. Dr. Jessica Maloh, Naturopathic Doctor and Head of Naturopathic Medicine at Codex Labs, will be attending the event and presenting a research poster that highlights the use of oral probiotics as adjunctive interventions for acne. 'Acne is one of the most common skin conditions affecting adolescents, often impacting not only the skin, but also self-esteem and quality of life,' says Dr. Maloh. 'At the SPD, I'm excited to share a summary of the research on the adjunctive use of oral probiotics in acne management- an intervention that may complement conventional dermatologic treatments like antibiotics and oral isotretinoin. Integrative strategies like this have been found to enhance acne treatment efficacy while also supporting the gut microbiome.' Codex Labs is honored to participate in the 50th Annual Meeting and looks forward to showcasing its products and findings. Dr. Maloh invites guests to the Networking Reception and to visit her team's presentation to learn more about their skincare breakthroughs and the latest in integrative dermatology research. Event Details: Location: The Westin Seattle, located at 1900 5th Ave, Seattle, WA 98101. For more information about Codex Labs and its products, please visit If you are interested in learning more about Codex Labs' participation in The SPD's 50th Annual Meeting, please contact About Codex Labs: Based in Silicon Valley and led by scientist Dr. Barb Paldus, Codex Labs is committed to creating highly effective, clinically proven, microbiome-supporting skin-gut-brain-biome solutions that contain potent, biotech-derived plant-based actives. Codex Labs' products focus on restoring/protecting the skin barrier, managing inflammation, and addressing skin conditions associated with aging, acne, eczema, and psoriasis. The brand has been heralded by integrative dermatologists and naturopathic doctors for creating the next generation of effective, vegan, cruelty-free, and sustainable plant-based solutions.
CTV News
21 hours ago
- CTV News
Here's why teens don't belong on dating apps
Nearly one-in-four teens ages 13 through 18 have used dating apps, according to the Journal of Psychopathology and Clinical Science. (Julio Lopez/Pexels) Teenagers are using dating apps more than we previously knew, according to research published this week in the Journal of Psychopathology and Clinical Science. The study found that 23.5 per cent of teens ages 13 through 18 used dating apps over a six-month period, which is more than past estimates. The study is believed to be the first to track how teens use dating apps by recording their keyboard activity rather than relying on self-reports, according to the researchers. The study found that teens who used dating apps didn't generally have more symptoms of mental health challenges after six months than those who didn't. However, those who used dating apps frequently were more likely to have symptoms of major depressive disorders. 'This study showed some support for dating app users having greater depressive symptoms and greater engagement in risky behaviors,' said Lilian Li, a postdoctoral fellow in the department of psychiatry and behavioral sciences at Northwestern University's Feinberg School of Medicine in Chicago and the study's lead author. It's unclear whether that's because the dating app users were harmed on the apps through things such as exposure to harassment or risky behaviors, Li said, or whether those who were depressed used dating apps because they had trouble connecting with others. Li cautioned that the study was small — it included 149 teens in the United States, 35 of whom used dating apps. And because it only tracked keyboard entries, it wasn't able to measure things such as lurking or liking and disliking profiles. There's still reason for parents to be concerned, because dating apps could also be harming kids in other ways. That's why, when I speak to parents and students about how to handle kids' use of apps, I suggest that teenagers not use online dating platforms at all. Teens can connect with predators online One reason I don't think teens belong on dating apps is because they're dangerous. Researchers have warned that registered sex offenders freely use online dating sites. Online dating particularly raises the risk of teens being catfished, manipulated into an emotional relationship with someone using an assumed identity. That creates the opportunity for the other person to convince the teen to share an intimate image, which can then be used for financial extortion or to pressure the victim into further exploitation. Wolf Image The dating app Tinder logo (Aamir Qureshi/AFP/Photographer: Aamir Qureshi/AFP/) These risks make dating apps dangerous for adults but even more so for teenagers, because the teenage brain is wired to accept greater risks in the pursuit of rewards, according to the UCLA Center for the Developing Adolescent. That's why it didn't surprise me that the new research found that teens who engaged in other risky behaviors, such as using substances and breaking rules, were more likely to use dating apps. We can't expect teenagers to consider that the person they think is their new boyfriend or girlfriend might actually be an adult cybercriminal. Teens also can't be expected to think through the potential consequences if they decide to meet up in person with someone they connected with online. 'Minors are not permitted on our dating apps, full stop,' said a spokesperson for the Match Group, which owns Tinder, the most-used dating app among teens in the study. 'Our platforms are for adults 18 and older, and we deploy industry-leading technology and human oversight to keep underage users off them. Our brands deploy sophisticated safety tools including AI-powered age verification, ID verification, and device blocking, as well as human moderators to proactively detect and remove minors and bad actors. 'We work with longstanding partners like THORN to enhance safety measures and, this year, supported the founding of ROOST, a nonprofit focused on building scalable tools for child safety. We continue to invest in cutting-edge tools, technology, and partnerships to help ensure our platforms remain safe for the communities we serve.' The spokesperson also noted that the Match Group offers a safety tool to conduct background checks on users and that the statistics in the new research include social discovery apps, which are different from dating apps. Dating apps don't teach teens to have healthy relationships The problem is not just that dating apps are dangerous, which they can be. They can also send the wrong signals to young people about human relationships. If you want to establish and maintain a relationship with someone in person, you generally have to learn things like how to have a two-way conversation, show consideration for the other person and even resolve disagreements that might come up. Grindr A phone screen shows multiple apps, including Grindr, a dating app for gay men. These are all skills that teens need to practice and which will serve them well in many aspects of their lives. They'll not only help youth deal with people such as future professors and employers but will likely make them happier over the long run. Close relationships are even more important for our happiness than things such as money or fame and are also important to our health, Harvard University researchers found in one of the longest studies of adults ever conducted. In interviews for my book, people told me they felt dating app users invest less in the relationships they form with their 'matches' because the apps convey the impression that there are always more people available to swipe on. 'If someone upsets you for the smallest reason, you can go to a dating app and find someone else,' one woman told me. So teens are learning they can walk away from dating apps feeling like romantic partners are easily obtained and let go, rather than learning to refine skills to maintain close offline relationships. There are other ways to meet their needs To start conversations about these concerns, parents should check in with teens on whether they're using or want to use dating apps. If teens say yes, it's an opportunity to consider how they can meet their needs in other ways. For example, if teens are lonely or want to find a romantic partner, one of the best things we can do is let them get together with peers in person. They can connect with friends and even potential romantic partners who share similar interests by signing up for extracurricular activities. It is also an important way of helping teens feel like they matter, which is one of the best means for promoting well-being. The new study found that dating apps may give teens who are sexual and gender minorities in their communities ways of making valuable social connections. It would be even better, however, for parents to explore how such teens can make those connections by meeting up with the kinds of people they want to know face-to-face. Some teens may also want to use dating apps because some platforms have suggested they have algorithms that can match people with their soulmates — or at least compatible romantic partners. However, decades of research tells us this isn't possible, because it turns out that people's personality traits don't actually predict whether they'll do well as a couple. Prepare teens for using dating apps in the future Still, 30 per cent of Americans have used a dating app or site at some point, according to a 2023 Pew Research Center survey, so it's possible that your teen will find a way to evade your rules against using them now or will use one in the future. That's why you should talk to teens about how to stay safe on dating apps if they do use them at any point in their lives. I recommend video chatting with people before meeting up in person to confirm that they appear to be who they say they are, meeting in public places, telling loved ones where you're meeting, telling the person you're meeting that your loved ones know where you are, and not being alone with someone until you're confident you can trust them. I know parents think their children would never use a dating app or go meet a stranger they only know online. But since this new research suggests teens are using these apps more than parents may realize, it's best to be prepared. Whether teens are just breaking your rules or getting into trouble online, they are missing out on learning to establish healthy relationships face-to-face. That's why parents should talk to teens now about these concerns, helping them get their dating lives started on the right track instead of merely swiping right.
